S. Knox

Articles by S. Knox

Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology

ByJ. M. Vose,A. D. Zelenetz,A. Rohatiner,S. Knox,R. Stagg,S. Kroll,G. Tidmarsh,M. S. Kaminski

March 1st 2000

Iodine-131 tositumomab (Bexxar) is a new radioimmunotherapy in development for the treatment of patients with low-grade or transformed low-grade non-Hodgkin’s lymphoma. The data from five phase I-III studies, which enrolled patients with low-

Latest Updated Articles

Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology
March 1st 2000

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC

107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)

109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR